Table 3.
Summary Of Glembatumumab Vedotin Pharmacokinetics In Patients 12 – 14 Years Of Age
| n | Cmax (μg/mL) | Tmax (hr) | T1/2 (hr) | AUC0–3w (hr-μg/mL) | Vz (mL/kg) | Cl (mL/hr/kg) | |
|---|---|---|---|---|---|---|---|
| TA | 4 | 48.8 ± 10.0 | 1.8 ± 0.5 | 35.2 ± 6.4 | 2319 ± 334 | 42.5 ± 11.7 | 0.8 ± 0.1 |
| ADC | 4 | 59.8 ± 16.3 | 3.3 ± 1.7 | 29.1 ± 8.4 | 2260 ± 750 | 37.9 ± 16.3 | 0.9 ± 0.3 |
| MMAE | 4 | 0.006 ± 0.003 | 96 ± 0.0 | 62.6 ± 14.6 | 1.28 ± 0.88 | 42,802 ± 28,786 | 533 ± 468 |
TA – total antibody; ADC – antibody drug conjugate; MMAE - monomethyl auristatin E; n – number; Cmax – maximum concentration; T1/2 – half life; AUC – area under the curve; Vz – volume of distribution; Cl – clearance